Indo-Bangla Pharmaceuticals Limited announcements
129 Dhaka Stock Exchange announcements for Indo-Bangla Pharmaceuticals Limited (IBP) since 2018: results, dividends, board meetings, AGMs, record dates and other price-sensitive information. Showing 2024 (21).
- Q1 Financials
(Q1 Un-audited): EPS was Tk. (0.03) for July-September 2024 as against Tk. 0.01 for July-September 2023; NOCFPS was Tk. (0.06) for July-September 2024 as against Tk. 0.09 for July-September 2023. NAV per share was Tk. 13.58 as on September 30, 2024 and Tk. 13.60 as on June 30, 2024. Reasons for Significant Deviation: (cont.1) (cont. news of IBP): EPS has been decreased as compared to the same period of the previous year due to decrease in sales revenue and also Increase in production cost for increase in all raw material prices and significant volatility of the foreign currency market. NOCFPS has been decreased during the period due to decreased collection from customers than payment to Suppliers. (end) (cont. news of IBP): During the period sales revenue has decreased by 67.49% from BDT 85,297,926 to BDT 27,732,408 in comparison to the same period of the previous year due to limitation for opening L/C to import raw materials which troubled our production and sales. (cont.2)
- Board Meeting schedule under LR 16(1)
As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on December 22, 2024 at 4:00 PM to consider, among others, un-audited financial statements of the Company for the First Quarter (Q1) period ended September 30, 2024.
- Qualified Opinion, Emphasis of Matter & Going Concern
The auditor of the company has given the "Qualified Opinion", "Emphasis of Matter" & "Material Uncertainty Related to Going Concern" in the auditor's report for the year ended June 30, 2024. To view the details please visit: https://www.dsebd.org/Auditors_opinion/2024/November/IndoBanglA_2024.pdf
- Resumption after Record date
Trading of the shares of the company will resume on 04.12.2024.
- Suspension for Record Date
Trading of the shares the company will remain suspended on record date i.e., 03.12.2024.
- Spot News
Trading of the shares of the company will be allowed only in the Spot Market and Block transaction will also be settled as per spot settlement cycle with cum benefit from 28.11.2024 to 02.12.2024 and trading of the shares will remain suspended on record date i.e., 03.12.2024.
- Dividend Declaration
The Board of Directors has recommended 0.10% Cash Dividend for the year ended June 30, 2024. Date of AGM: 26.12.2024, Time: 11:00 AM, Venue: Hybrid System. Record Date: 03.12.2024. The Company has also reported EPS of Tk. (0.35), NAV per share of Tk. 13.60 and NOCFPS of Tk. 0.29 for the year ended June 30, 2024 as against Tk. 0.07, Tk. 13.96 and Tk. 0.79 respectively for the year ended June 30, 2023.
- Price Limit Open
There will be no price limit on the trading of the shares of the Company today (13.11.2024) following its corporate declaration.
- Reschedule of Board Meeting under LR 19(1)
The Company has further informed that, the Board meeting under LR 19(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, will be held on November 12, 2024 at 4:00 PM to consider, among others, audited financial statements of the Company for the year ended June 30, 2024.
- Postponement of Board Meeting schedule under LR 19(1)
The Company has further informed that due to unavoidable circumstances, the meeting scheduled to be held on October 28, 2024 at 4:00 PM as per LR 19(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, to consider, among others, audited financial statements of the Company for the year ended June 30, 2024, has been postponed. New date and time of the meeting will be notified later.
- Board Meeting schedule under LR 19(1)
As per Regulation 19(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on October 28, 2024 at 4:00 PM to consider, among others, audited financial statements of the Company for the year ended June 30, 2024.
- Category Change
The Company will be placed in 'Z' category from existing 'B' category with effect from September 26, 2024 as per provision 1(e) of BSEC Directive No. BSEC/CMRRCD/2009-193/77, dated May 20, 2024.
- Prohibition on providing loan facilities to purchase securities
The Stock Brokers and Merchant Bankers are requested to abstain from providing loan facilities to purchase security of Indo-Bangla Pharmaceuticals Limited with effect from September 26, 2024 as per BSEC Directive No. BSEC/CMRRCD/2009-193/32 dated December 26, 2021.
- Sale Confirmation of a Sponsor
Ms. Sayeda Huq, a Sponsor of the company, has further informed that she has completed sale of her entire holding 24,47,182 shares of the Company at prevailing market price through Dhaka Stock Exchange PLC. as per declaration disseminated on 31.03.2024.
- Q3 Financials
(Q3 Un-audited): EPS was Tk. (0.08) for January-March 2024 as against Tk. 0.01 for January-March 2023; EPS was Tk. (0.13) for July 2023-March 2024 as against Tk. 0.10 for July 2022-March 2023. NOCFPS was Tk. 0.19 for July 2023-March 2024 as against Tk. 0.06 for July 2022-March 2023. NAV per share was Tk. 13.83 as on March 31, 2024 and Tk. 13.96 as on June 30, 2023.
- Board Meeting schedule under LR 16(1)
As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on April 30, 2024 at 03:30 PM to consider, among others, un-audited financial statements of the Company for the Third Quarter (Q3) period ended March 31, 2024.
- Sale Declaration of a Sponsor
Ms. Sayeda Huq, a Sponsor of the company, has expressed her intention to sell her entire holding of 24,47,182 shares of the company at prevailing market price (in the Public/Block Market) through Dhaka Stock Exchange PLC. within April 30, 2024.
- (Q2 Un-audited): EPS was Tk. (0.06) for October-December 2023 as against Tk. (0.08) for October-December 2022; EPS was T
(Q2 Un-audited): EPS was Tk. (0.06) for October-December 2023 as against Tk. (0.08) for October-December 2022; EPS was Tk. (0.05) for July-December 2023 as against Tk. 0.09 for July-December 2022. NOCFPS was Tk. 0.23 for July-December 2023 as against Tk. 0.05 for July-December 2022. NAV per share was Tk. 13.91 as on December 31, 2023 and Tk. 13.96 as on June 30, 2023. Reasons for deviation of EPS, NOCFPS and NAVPS: (cont.)
- Q2 Financials
(Continuation news of IBP): EPS has been decreased compared to the same period of the previous year due to decreased in sales revenue and also increased cost of revenue due to disruption in supply chain for crisis of US dollar, limitation for opening L/C to import raw materials, Russia and Ukraine War and price hike of Electricity. NOCFPS has been increased due to decrease in supplier's payment during the reporting period. NAVPS has also been decreased due to net loss after tax. (end)
The first part of this announcement is missing from the archive. - Board Meeting schedule under LR 16(1)
As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on January 30, 2024 at 4:00 PM to consider, among others, un-audited financial statements of the Company for the Second Quarter (Q2) period ended December 31, 2023.
- Emerging Credit Rating Limited (ECRL) has affirmed surveillance rating of the Company as \"BBB\" in the long term and \"
Emerging Credit Rating Limited (ECRL) has affirmed surveillance rating of the Company as \"BBB\" in the long term and \"ST-3\" in the short term along with a Stable outlook based on audited financial statements up to June 30, 2023, and other relevant quantitative as well as qualitative information up to the date of rating.
Source: Dhaka Stock Exchange announcements. Some posts before 2014 have no title, and 2014–2020 coverage is incomplete.